Dasatinib
Brand name: Sprycel
Rank #123 of 500 drugs by total cost
$136.8M
Total Cost
10,389
Total Claims
$136.8M
Total Cost
591
Prescribers
$13K
Cost per Claim
0
Beneficiaries
10,485
30-Day Fills
$231K
Avg Cost/Provider
18
Avg Claims/Provider
About Dasatinib
Dasatinib (sold as Sprycel) was prescribed 10,389 times by 591 Medicare Part D providers in 2023, costing the program $136.8M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 120 | Emtricitab/Rilpiviri/Tenof Ala (Odefsey) | $144.1M | 37,441 |
| 121 | Eltrombopag Olamine (Promacta) | $142.8M | 10,876 |
| 122 | Alpha-1-Proteinase Inhibitor (Prolastin C) | $137.9M | 12,352 |
| 123 | Dasatinib (Sprycel) | $136.8M | 10,389 |
| 124 | Oxycodone Hcl/Acetaminophen (Oxycodone-Acetaminophen) | $136.4M | 3,487,099 |
| 125 | Buprenorphine Hcl/Naloxone Hcl (Buprenorphine-Naloxone) | $135.8M | 696,008 |
| 126 | Cenegermin-Bkbj (Oxervate) | $133.5M | 3,601 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology